Molecular guided therapies: a practice-changing step forward in cancer of unknown primary management
- PMID: 39096927
- DOI: 10.1016/S0140-6736(24)00975-9
Molecular guided therapies: a practice-changing step forward in cancer of unknown primary management
Conflict of interest statement
ER reports grants from Gilead (institutional); travel, accommodations, and expenses fees from Pfizer, Roche, Mundipharma, Eli Lilly, Gilead, and Novartis; and honoraria for lectures or presentations from Eli Lilly, Seagen, and Novartis none of which are related to the treatment of CUP. FAG reports speakers bureau and consultancy fees as a medical adviser from Hologic–Biotheranostics that has a molecular classifier assay for CUP. NP declares no competing interests.
Comment on
-
Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study.Lancet. 2024 Aug 10;404(10452):527-539. doi: 10.1016/S0140-6736(24)00814-6. Epub 2024 Jul 31. Lancet. 2024. PMID: 39096924 Clinical Trial.
Similar articles
-
Management of cancer from an unknown primary.Expert Opin Pharmacother. 2007 Mar;8(4):445-55. doi: 10.1517/14656566.8.4.445. Expert Opin Pharmacother. 2007. PMID: 17309339 Review.
-
Unknown primary tumors: is there a future therapeutic role for immune checkpoint inhibitors?Future Oncol. 2016 Feb;12(4):429-31. doi: 10.2217/fon.15.329. Epub 2016 Jan 18. Future Oncol. 2016. PMID: 26776661 No abstract available.
-
Cancer of Unknown Primary Site: New Treatment Paradigms in the Era of Precision Medicine.Am Soc Clin Oncol Educ Book. 2018 May 23;38:20-25. doi: 10.1200/EDBK_100014. Am Soc Clin Oncol Educ Book. 2018. PMID: 30231392 Review. No abstract available.
-
The current evidence for a biomarker-based approach in cancer of unknown primary.Cancer Treat Rev. 2018 Jun;67:21-28. doi: 10.1016/j.ctrv.2018.04.011. Epub 2018 May 2. Cancer Treat Rev. 2018. PMID: 29751335 Review.
-
Progress in refining the clinical management of cancer of unknown primary in the molecular era.Nat Rev Clin Oncol. 2020 Sep;17(9):541-554. doi: 10.1038/s41571-020-0359-1. Epub 2020 Apr 29. Nat Rev Clin Oncol. 2020. PMID: 32350398 Review.
Cited by
-
Treatments and cancer: implications for radiologists.Front Immunol. 2025 Apr 16;16:1564909. doi: 10.3389/fimmu.2025.1564909. eCollection 2025. Front Immunol. 2025. PMID: 40308594 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources